Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

PURPOSE The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of chronic lymphocytic leukemia (CLL). Based on excellent results with the chemotherapy-only regimen fludarabine, cyclophosphamide, and mitoxantrone (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. PATIENTS AND METHODS Seventy-two untreated CLL patients age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), fludarabine 25 mg/m(2) IV on days 1 to 3, cyclophosphamide 200 mg/m(2) on days 1 to 3, and mitoxantrone 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. Patients achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS The overall response, minimal residual disease (MRD) -negative complete response (CR), MRD-positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe neutropenia developed in 13% of patients. Major and minor infections were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum beta2-microglobulin levels correlated with a lower CR rate. CONCLUSION R-FCM is highly effective in previously untreated CLL, with an 82% CR rate and a high proportion of MRD-negative CRs (46%). Treatment toxicity is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum beta2-microglobulin levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

[1]  K. Foon,et al.  Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Schuster,et al.  Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Zelenetz,et al.  Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Berrebi,et al.  Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL) , 2008 .

[5]  W. Chan,et al.  Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Do,et al.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.

[7]  Emili Montserrat,et al.  New prognostic markers in chronic lymphocytic leukemia. , 2008, Blood reviews.

[8]  E. Giné,et al.  Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication , 2008, Clinical Cancer Research.

[9]  T. Robak,et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[11]  J. Byrd,et al.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.

[12]  M. Grever,et al.  Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[14]  M. Caligiuri,et al.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.

[16]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Fegan,et al.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Montserrat Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Byrd,et al.  Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. , 2005, Blood.

[20]  謙 大間知 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.Coiffier B,et al.N Engl J Med 2002;346(4):235-42--CHOP+リツキシマブ併用療法は、CHOP療法を上回る治療法であり、DLBCLの治療動向に大きなimpactを与えた , 2004 .

[21]  D. Catovsky,et al.  Fludarabine, Cyclophosphamide and Mitoxantrone in Relapsed or Refractory Chronic Lymphocytic Leukemia and Low Grade Non-Hodgkin's Lymphoma , 2004, Leukemia & lymphoma.

[22]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[23]  E. Giné,et al.  Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia , 2002, British journal of haematology.

[24]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[25]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[26]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[27]  P. Feugier,et al.  Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.

[28]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[29]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[30]  M. Błasińska-Morawiec,et al.  Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. , 2000, Blood.

[31]  E. Montserrat,et al.  In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[32]  E J Freireich,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.

[33]  D. Colomer,et al.  Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B‐chronic lymphocytic leukaemia cells , 1998, British journal of haematology.

[34]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[35]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.

[36]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[37]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.